Trial Title:
Daratumumab in STK11 Mutated NSCLC
NCT ID:
NCT05807048
Condition:
Non-small Cell Lung Cancer With STK11/LKB1 Mutation
Conditions: Official terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Daratumumab
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Daratumumab and Hyaluronidase-fihj
Description:
DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection for subcutaneous use.
Supplied as individually packaged single-dose vials providing 1,800 mg of daratumumab and
30,000 units of hyaluronidase per 15 mL.
Arm group label:
Patients with STK11/LKB1-Mutated NSCLC
Other name:
DARZALEX FASPRO
Intervention type:
Drug
Intervention name:
Pre-Intervention Medication
Description:
The following pre-medications will be administered 1-3 hours before each dose of DARZALEX
FASPRO:
- Acetaminophen 650 to 1,000 mg orally
- Diphenhydramine 25 to 50 mg (or equivalent) orally or intravenously
- Montelukast 10mg PO prior to DARZALEX FASPRO®.
- Methylprednisolone 100 mg (or equivalent) orally or intravenously
Arm group label:
Patients with STK11/LKB1-Mutated NSCLC
Intervention type:
Drug
Intervention name:
Post-Intervention Medication
Description:
The following post-medications will be administered:
- Methylprednisolone 20 mg (or an equivalent dose of an intermediate- or long acting
corticosteroid) orally for 2 days starting the day after the administration of
DARZALEX FASPRO®.
- Patients with a history of chronic obstructive pulmonary disease will be prescribed
short and long-acting bronchodilators and inhaled corticosteroids.
- Antiviral prophylaxis for herpes zoster reactivation must be initiated within one
week of daratumumab hyaluronidase-fihj administration and continued for 3 months
following the end of treatment.
Arm group label:
Patients with STK11/LKB1-Mutated NSCLC
Summary:
This is a single-arm study of daratumumab in metastatic non-small cell lung cancer
(NSCLC) patients with an STK11/LKB1 mutation. Patients will have received previous
standard of care treatment including chemotherapy, immunotherapy and targeted therapy.
Patients will be treated with the standard subcutaneous dosing of daratumumab (weekly for
8 administrations, then every 2 weeks for 8 administrations then every 4 weeks until
progression). All follow-up visits and imaging will be performed as per standard of care.
This is a signal finding study and an overall response rate ≥20% is considered clinically
meaningful.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Participant must be ≥ 18 years of age and satisfy the legal age of consent in the
jurisdiction in which the study is being conducted.
- Participant must have histologically or cytologically confirmed NSCLC that is
metastatic or unresectable.
- Participants must have either progressed after prior immunotherapy with a PD-(L)1
inhibitor, platinum doublet chemotherapy and standard of care targeted therapy (if
presence of an activating mutation is identified) for metastatic disease, be
ineligible for, or have refused all therapeutic options. In cases where participants
refuse currently available therapeutic options, this must be documented in the study
records.
- Participants must have previously identified STK11/LKB1 mutation (identified locally
in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory [or
equivalent])
- Participant must have organ and bone marrow function as follows:
- Hemoglobin ≥9 g/dL
- Absolute blood neutrophil count (ANC) ≥1.5 x 109 /L
- Platelets ≥75 x 109 /L
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 x upper limit of
normal (ULN)
- Total bilirubin =1.5 x ULN; participants with Gilbert's syndrome can enroll if
conjugated bilirubin is within normal limits.
- Serum creatinine <1.5 x ULN or if available, calculated or measured creatinine
clearance; >50 mL/min/1.73 m2
- Before enrollment, a woman must be either:
- Not of childbearing potential: postmenopausal (>45 years of age with amenorrhea
for at least 12 months); permanently sterilized (eg, bilateral tubal occlusion
[which includes tubal ligation procedures as consistent with local
regulations], hysterectomy, bilateral salpingectomy, bilateral oophorectomy);
or otherwise be incapable of pregnancy,
- Of childbearing potential and practicing a highly effective method(s) of birth
control consistent with local regulations regarding the use of birth control
methods for participants participating in clinical studies, described as
follows: practicing true abstinence (when this is in line with the preferred
and usual lifestyle of the participant), which is defined as refraining from
heterosexual intercourse during the entire period of the study, including up to
6 months after the last dose of study drug is given; OR have a sole partner who
is vasectomized; OR practicing 2 methods of contraception, including one highly
effective method (ie, established use of oral, injected or implanted hormonal
methods of contraception; placement of an intrauterine device [IUD] or
intrauterine system [IUS]), AND, a second method, (eg, condom with spermicidal
foam/gel/film/cream/suppository or occlusive cap [diaphragm or cervical/vault
caps] with spermicidal foam/gel/film/cream/suppository).
- Note: If the childbearing potential changes after start of the study (eg, woman
who is not heterosexually active becomes active, postmenopausal woman
experiences menarche) the woman must begin a highly effective method of birth
control, as described above.
- A woman of childbearing potential must have a negative serum (β-human chorionic
gonadotropin [β-hCG]) at Screening and a negative urine or serum pregnancy test
within 24 hours before the first dose of study drug.
- A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted
reproduction during the study and for 6 months after receiving the last dose of
study drug.
- A man who is sexually active with a woman of childbearing potential must agree to
use a condom and his partner must also be practicing a highly effective method of
contraception (ie.. established use of oral, injected or implanted hormonal methods
of contraception; placement of an IUD or IUS). If the participant is vasectomized,
he must still use a condom, but his female partner is not required to use
contraception. The participant must also not donate sperm during the study and for 6
months after receiving the last dose of study drug.
- Participant must be willing and able to adhere to the prohibitions and restrictions
specified in this protocol, including the agreement by both male and female
participants to continue contraception throughout the study and through 6 months
after the last dose of study drug.
- Each participant must sign an informed consent form (ICF) indicating that he or she
understands the study's purpose and the procedures required for the study and is
willing to participate in the study, including the requirement to provide
information during the Follow-up period.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation
in this study:
- Participant has uncontrolled inter-current illness, including but not limited to
poorly controlled hypertension or diabetes, ongoing or active systemic infection
(ie, has discontinued all antibiotics for at least one week prior to first dose of
study drug), diagnosed or suspected viral infection (except for HIV), or psychiatric
illness/social situation that would limit compliance with study requirements,
including ability to self-care for anticipated toxicities (eg. rash or paronychia).
- Participants with medical conditions requiring chronic continuous oxygen therapy are
excluded.
- Participants with a history of chronic obstructive pulmonary disease (COPD) with
grade ≥3 breathlessness on the modified medical research council (mMRC) dyspnea
scale are excluded.
- Have known moderate or severe persistent asthma within the past 2 years, or current
uncontrolled asthma of any classification.
- Participant has a history of clinically significant cardiovascular disease
including, but not limited to:
- Diagnosis of deep vein thrombosis or pulmonary embolism within 4 weeks prior to
the first dose of study drug, or any of the following within 6 months prior to
the first dose of study drug: myocardial infarction, unstable angina, stroke,
transient ischemic attack, coronary/peripheral artery bypass graft, or any
acute coronary syndrome. Clinically non-significant thrombosis, such as
non-obstructive catheter-associated clots, are not exclusionary.
- Prolonged QTcF interval >480 msec or clinically significant cardiac arrhythmia
or electrophysiologic disease (eg, placement of implantable cardioverter
defibrillator or atrial fibrillation with uncontrolled rate). Note:
Participants with cardiac pacemakers who are clinically stable are eligible.
- Uncontrolled (persistent) hypertension: systolic blood pressure >180 mm Hg;
diastolic blood pressure >100 mm Hg
- Congestive heart failure defined as New York Heart Association (NYHA) class
III-IV or Hospitalization for congestive heart failure (any NYHA class) within
6 months of study Day 1
- Pericarditis/clinically significant pericardial effusion
- Myocarditis
- Participant has had prior chemotherapy, targeted cancer therapy, or treatment with
an investigational anti-cancer agent within 2 weeks or 4 half-lives, whichever is
longer, before the first administration of study drug; or participant has received
prior immunotherapy within 6 weeks before the first administration of study drug.
For agents with long half-lives, the maximum required time since last dose is 4
weeks. Toxicities from previous anticancer therapies should have resolved to
baseline levels or to Grade 1 or less, (except for alopecia [any grade], Grade ≤2
peripheral neuropathy, and Grade <2 hypothyroidism stable on hormone replacement).
Autoimmune toxicities from previous immunotherapy must be fully resolved to baseline
levels.
- Localized, radiotherapy for palliative purposes must be completed at least 7 days
prior to treatment with daratumumab and hyaluronidase.
- Participants with untreated brain metastases. Participants with locally treated
metastases that are clinically stable and asymptomatic for at least 2 weeks and who
are off or receiving low-dose corticosteroid treatment (≤10 mg prednisone or
equivalent) for at least 2 weeks prior to study treatment are eligible.
- Participant has leptomeningeal disease.
- Participant has an active malignancy other than the disease under study requiring
treatment or a history of malignancy unless all treatment of that malignancy was
completed at least 2 years before consent and the patient has no evidence of disease
before the date of randomization. Exceptions are squamous and basal cell carcinomas
of the skin, carcinoma in situ of the cervix or breast, or other non-invasive lesion
that in the opinion of the investigator is considered cured with minimal risk of
recurrence within 3 years.
- Participant has known allergies, hypersensitivity, or intolerance to daratumumab or
hyaluronidase or its excipients.
- Participants with known allergies, hypersensitivity to any component of montelukast.
- Participant has received an investigational drug (including investigational vaccines
but not including anti-cancer therapy [refer to Exclusion Criterion #3]) or used an
invasive investigational medical device within 6 weeks before the planned first dose
of study drug.
- Participant is a woman who is pregnant, or breast-feeding, or planning to become
pregnant while enrolled in this study or within 6 months after the last dose of
study drug.
- Participant has any condition for which, in the opinion of the investigator,
participation would not be in the best interest of the participant (eg, compromise
the well-being) or that could prevent, limit, or confound the protocol-specified
assessments.
- Participant has at Screening:
- Positive hepatitis B (hepatitis B virus [HBV]) surface antigen (HBsAg) Subjects
with resolved infection (ie, subjects who are HBsAg negative but positive for
antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to
hepatitis B surface antigen [anti-HBs]) must be screened using real-time
polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA
levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with
serologic findings suggestive of HBV vaccination (anti-HBs positivity as the
only serologic marker) AND a known history of prior HBV vaccination, do not
need to be tested for HBV DNA by PCR.
- Positive hepatitis C antibody (anti-HCV). Note: Participants with a prior
history of HCV, who have completed antiviral treatment and have a sustained
virologic response, defined as aviremia at least 12 weeks after completion of
antiviral therapy are eligible. Patients who completed treatment for hepatitis
C at least 6 months prior to screening and have no detectable circulating HCV
during screening may participate in the study. Such patients will be required
to undergo regular assessments for HCV reactivation during the study and are to
be withdrawn from the study if he/she test positive at any time during the
study.
- Other clinically active infectious liver disease.
- Seropositive for human immunodeficiency virus.
- Participant has had prior therapy with daratumumab.
- Have had major surgery within 2 weeks before randomization or will not have fully
recovered from surgery, or has surgery planned during the time the patient is
expected to participate in the study or within 2 weeks after the last dose of study
treatment. Note, patients with planned surgical procedures to be conducted under
local anesthesia may participate.
- Have received vaccination with live attenuated vaccines within 4 weeks of first
study agent administration.
Gender:
All
Minimum age:
18 Years
Maximum age:
100 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
NYU Langone Health
Address:
City:
New York
Zip:
10016
Country:
United States
Status:
Recruiting
Start date:
June 1, 2023
Completion date:
December 2025
Lead sponsor:
Agency:
NYU Langone Health
Agency class:
Other
Source:
NYU Langone Health
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05807048
